NFE2L2 and cancer: Somatic mutations of the KEAP1 gene, causing the constitutive activation of NRF2, were found among lung cancer patients and confer a robust growth advantage and tumor-initiating ability on cancers through the promotion of metabolic reprogramming and enhancement of cancer stemness [18,19,20,21,22,23].